Those of us without evidence of cognitive impairment certainly remember the hubbub over the release of Aducanumab, the first FDA-approved drug to treat Alzheimer’s Disease. A short, to-the-point research letter in JAMA clarifies why it has the potential for abuse – and what the FDA needs to do to prevent it.
